Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.53 |
| ▸ | ATXN2 | Q99700 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704607 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL8323435 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL30553394 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| Iodide SCHEMBL30143510 | 0.85 | ENPP2 (0.53) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL25324994 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL27194502 | 0.84 | ENPP2 (0.52) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL10153538 | 0.83 | MEN1 (0.54) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL25326302 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL25327822 | 0.82 | ENPP2 (0.51) | SMN1; SMN2CYP2C19ENPP2ATXN2NPC1 | |
| SCHEMBL16616056 | 0.81 | ENPP2 (0.55) | ENPP2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022237858-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9493486-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHES INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | SMN1; SMN2 4525/4885CYP2C19 4729/4885ENPP2 1/4885 |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | SMN1; SMN2 4451/4885CYP2C19 4800/4885ENPP2 1/4885 |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | ENPP2, DAPK1, DAPK2 | SMN1; SMN2 4525/4885CYP2C19 4729/4885ENPP2 1/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | SMN1; SMN2 3255/4885CYP2C19 898/4885ENPP2 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.